Open Access
ISG15 deficiency restricts HIV-1 infection
Author(s) -
Denise Jurczyszak,
Lara Manganaro,
Sofija Buta,
Conor Gruber,
Marta Martín-Fernández,
Justin Taft,
Roosheel S. Patel,
Melissa Cipolla,
Hala Alshammary,
Lubbertus C. F. Mulder,
Ravi Sachidanandam,
Dusan Bogunovic,
Viviana Simon
Publication year - 2022
Publication title -
plos pathogens
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.719
H-Index - 206
eISSN - 1553-7374
pISSN - 1553-7366
DOI - 10.1371/journal.ppat.1010405
Subject(s) - isg15 , biology , interferon , interferon stimulated gene , proinflammatory cytokine , interferon type i , virology , immunology , gene , genetics , immune system , inflammation , innate immune system , ubiquitin
Type I interferons (IFN-Is) are a group of potent inflammatory and antiviral cytokines. They induce IFN stimulated genes (ISGs), which act as proinflammatory mediators, antiviral effectors, and negative regulators of the IFN-I signaling cascade itself. One such regulator is interferon stimulated gene 15 (ISG15). Humans with complete ISG15 deficiency express persistently elevated levels of ISGs, and consequently, exhibit broad spectrum resistance to viral infection. Here, we demonstrate that IFN-I primed fibroblasts derived from ISG15-deficient individuals are more resistant to infection with single-cycle HIV-1 compared to healthy control fibroblasts. Complementation with both wild-type (WT) ISG15 and ISG15ΔGG (incapable of ISGylation while retaining negative regulation activity) was sufficient to reverse this phenotype, restoring susceptibility to infection to levels comparable to WT cells. Furthermore, CRISPR-edited ISG15 ko primary CD4 + T cells were less susceptible to HIV-1 infection compared to cells treated with non-targeting controls. Transcriptome analysis of these CRISPR-edited ISG15 ko primary CD4 + T cells recapitulated the ISG signatures of ISG15 deficient patients. Taken together, we document that the increased broad-spectrum viral resistance in ISG15-deficiency also extends to HIV-1 and is driven by a combination of T-cell-specific ISGs, with both known and unknown functions, predicted to target HIV-1 replication at multiple steps.